KOD - Coronavirus Has Presented A Buying Opportunity In Kodiak Sciences
For all those who missed the train in 2019, the coronavirus pandemic has presented another chance to pick up Kodiak Sciences (KOD) stock. Let us see, what makes the company a solid buy at these share price levels.
Company overview
Founded in 2009, Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing biologic therapeutics to treat retinal diseases. The company is headquartered in Palo Alto, California and went public in October 2018.
Kodiak Sciences is leveraging its proprietary ABC (Antibody Biopolymer Conjugate) platform to develop mono, bi-specific, and triplet anti-VEGF (vascular endothelial